Global Statistics

All countries
164,283,440
Confirmed
Updated on May 18, 2021 1:01 am
All countries
144,221,084
Recovered
Updated on May 18, 2021 1:01 am
All countries
3,404,746
Deaths
Updated on May 18, 2021 1:01 am
Tuesday, May 18, 2021

Global Statistics

All countries
164,283,440
Confirmed
Updated on May 18, 2021 1:01 am
All countries
144,221,084
Recovered
Updated on May 18, 2021 1:01 am
All countries
3,404,746
Deaths
Updated on May 18, 2021 1:01 am
Molderizer and Safe Shield

‘Nanotraps’ capture coronavirus in the body for immune system to kill

Coronavirus live updates: Hugs and indoor dining allowed in England as restrictions ease

Over the past week, Taiwan has reported more than 700 local infections and raised its coronavirus alert level twice in the capital, Taipei,...

Gravitas: Is a 'medical cartel' controlling coronavirus supplies in the US?

Are six medical supplies companies profiteering from the Coronavirus outbreak in the US? A program created by US President Donald Trump's son-in-law Jared ... source

FDA authorizes Pfizer and BioNTech's Covid-19 vaccine for emergency use

The US Food and Drug Administration has authorized Pfizer and BioNTech's coronavirus vaccine for emergency use in the United States. CNN's Chris Cuomo ... source

Covid-19 and Vaccine News: Live Updates

Here’s what you need to know:VideotranscriptBacktranscriptBiden Says U.S. Will Be an ‘Arsenal of Vaccines’ for the WorldPresident Biden said on Monday the U.S....

Maine doctors answer COVID-19 vaccine questions

Get the Facts on the Vax: Maine doctors answer your COVID-19 vaccine questions


Researchers have designed a completely new potential treatment for COVID-19: nanoparticles that capture SARS-CoV-2 viruses within the body and then use the body’s own immune system to destroy them.

These “nanotraps” mimic the target cells the virus infects to attract the virus. When the virus binds to the nanotraps, the traps then sequester the virus from other cells and target it for destruction by the immune system.

In theory, these nanotraps could also be used on variants of the virus, leading to a potential new way to inhibit the virus going forward. Though the therapy remains in early stages of testing, the researchers envision it could be administered via a nasal spray as a treatment for COVID-19.

“Since the pandemic began, our research team has been developing this new way to treat COVID-19,” says Jun Huang, an assistant professor in the Pritzker School of Molecular Engineering at the University of Chicago, whose lab led the research. “We have done rigorous testing to prove that these nanotraps work, and we are excited about their potential.”

Building the perfect coronavirus trap

To design the nanotrap, the research team—led by postdoctoral scholar Min Chen and graduate student Jill Rosenberg—looked into the mechanism SARS-CoV-2 uses to bind to cells: a spike-like protein on its surface that binds to a human cell’s ACE2 receptor protein.

To create a trap that would bind to the virus in the same way, they designed nanoparticles with a high density of ACE2 proteins on their surface. Similarly, they designed other nanoparticles with neutralizing antibodies on their surfaces. (These antibodies are created inside the body when someone is infected and are designed to latch onto the coronavirus in various ways).

Made of FDA-approved polymers and phospholipids, the nanoparticles are about 500 nanometers in diameter—much smaller than a cell. That means the nanotraps can reach more areas inside the body and more effectively trap the virus.

Then, to check to make sure the tiny particles looked the way they expected, they partnered with the lab of Bozhi Tian to use electron microscopes to get a good look.

“From our imaging, we saw a solid core and a lipid bilayer shell. That’s the essential part because it mimics the cell,” says Tian, an associate professor appointed in the chemistry department.

The researchers tested the safety of the system in a mouse model and found no toxicity. They then tested the nanotraps against a pseudovirus—a less potent model of a virus that doesn’t replicate—in human lung cells in tissue culture plates and found that they completely blocked entry into the cells.

Once the pseudovirus bound itself to the nanoparticle—which in tests took about 10 minutes after injection—the nanoparticles used a molecule that calls the body’s macrophages to engulf and degrade the nanotrap. Macrophages will generally eat nanoparticles within the body, but the nanotrap molecule speeds up the process. The nanoparticles were cleared and degraded within 48 hours.

The researchers also tested the nanoparticles with a pseudovirus in an ex vivo lung perfusion system—a pair of donated lungs that is kept alive with a ventilator—and found that they completely blocked infection in the lungs.

They also collaborated with researchers at Argonne National Laboratory to test the nanotraps with a live virus (rather than a pseudovirus) in an in vitro system. They found that their system inhibited the virus 10 times better than neutralizing antibodies or soluble ACE2 alone.

What’s next?

Next the researchers hope to further test the system, including more tests with a live virus and on the many virus variants.

“That’s what is so powerful about this nanotrap,” Rosenberg says. “It’s easily modulated. We can switch out different antibodies or proteins or target different immune cells, based on what we need with new variants.”

The nanotraps can be stored in a standard freezer and could ultimately be given via an intranasal spray, which would place them directly in the respiratory system and make them most effective.

The nanotraps can be stored in a standard freezer and could ultimately be given via an intranasal spray.

The researchers say it is also possible to serve as a vaccine by optimizing the formulation.

“This nanomaterial engineering approach provides a versatile platform to clear viruses, and paves the way for designing next-generation vaccines and therapeutics,” says coauthor and graduate student Jiuyun Shi.

“This is the starting point,” Huang says. “We want to do something to help the world.”

The results appear in the journal Matter.

Funding came from the National Institutes of Health, National Science Foundation, and NIDDK.

Source: University of Chicago



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular

Coronavirus live updates: Hugs and indoor dining allowed in England as restrictions ease

Over the past week, Taiwan has reported more than 700 local infections and raised its coronavirus alert level twice in the capital, Taipei,...

Gravitas: Is a 'medical cartel' controlling coronavirus supplies in the US?

Are six medical supplies companies profiteering from the Coronavirus outbreak in the US? A program created by US President Donald Trump's son-in-law Jared ... source

FDA authorizes Pfizer and BioNTech's Covid-19 vaccine for emergency use

The US Food and Drug Administration has authorized Pfizer and BioNTech's coronavirus vaccine for emergency use in the United States. CNN's Chris Cuomo ... source

Related Articles

Coronavirus live updates: Hugs and indoor dining allowed in England as restrictions ease

Over the past week, Taiwan has reported more than 700 local infections and raised its coronavirus alert level twice in the capital, Taipei,...

Gravitas: Is a 'medical cartel' controlling coronavirus supplies in the US?

Are six medical supplies companies profiteering from the Coronavirus outbreak in the US? A program created by US President Donald Trump's son-in-law Jared ... source

FDA authorizes Pfizer and BioNTech's Covid-19 vaccine for emergency use

The US Food and Drug Administration has authorized Pfizer and BioNTech's coronavirus vaccine for emergency use in the United States. CNN's Chris Cuomo ... source